CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive ...
Patients without baseline CNS metastases were randomly assigned (1:1) to receive lapatinib-capecitabine (lapatinib 1,250 mg per day; capecitabine 2,000 mg/m 2 per day on days 1 to 14 every 21 days) or ...
Dec. 13 -- FRIDAY, Dec. 11 (HealthDay News) -- With a growing array of choices for breast cancer treatment, researchers are now trying to pinpoint the best combination of therapies or the best order ...
SAN ANTONIO — A new study strengthens the evidence that pathological complete response (pCR) is a good surrogate marker of longer-term efficacy in the neoadjuvant drug treatment of breast cancer. pCR, ...
Liquid biopsy of circulating tumor DNA (ctDNA) is an "efficient" way to monitor resistance to trastuzumab (Herceptin, Genentech) and spot emerging resistance mechanisms in metastatic human epidermal ...
Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a ...
Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the ...
While the treatment of breast cancer does not change with pregnancy status unless absolutely necessary, the health of the fetus must be carefully considered while deciding on the choice of therapy. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback